Virbac, FR0000031577

Virbac stock pre-market at EUR 311.75: plus 0.08 percent

Published on 09/30/2026 at 07:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac stock was at EUR 311.75 pre-market on September 30, 2026, up 0.08 percent versus the Lang & Schwarz prior close. The company reported first-half growth and confirmed its 2026 guidance on September 17.

Modernes Pharmawerk für Tiergesundheit in sonniger südfranzösischer Landschaft
Fotorealistische Aufnahme zeigt Veterinärpharma-Anlage von Virbac S.A., passend zu ISIN FR0000031577, moderner Standort Südfrankreich, Illustration mit AI erstellt.

Virbac stock was at EUR 311.75 pre-market at 7:54 a.m. CEST on September 30, 2026, according to Lang & Schwarz. The price was up 0.08 percent, or EUR 0.25, versus the Lang & Schwarz prior close of EUR 311.50.

First-half revenue growth

In a September 17, 2026 release, Virbac reported first-half 2026 revenue of EUR 768.0 million, an increase of 4.0 percent at actual exchange rates and 7.4 percent at constant exchange rates and scope compared with the first half of 2025.

The company reported adjusted EBIT before amortization of EUR 144.2 million, compared with EUR 135.0 million a year earlier. The adjusted EBIT margin was 18.8 percent, versus 18.3 percent in the first half of 2025. Consolidated net income rose 5.9 percent to EUR 87.1 million.

2026 guidance confirmed

Virbac said its full-year 2026 guidance remained unchanged and that its first-half performance positioned it to target the upper end of its revenue-growth range of 5.5 percent to 7.5 percent at constant rates and scope. The company expects adjusted recurring operating income of around 17 percent at constant exchange rates and scope, according to the company release.

Disclaimer...

en | FR0000031577 | VIRBAC | boerse | 70201832 | bgmi